EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

UMG1 Defines a Targetable Subset of T‐Cell Lymphomas and Enables Precision Immunotherapy With a First‐in‐Class CD3ε Bispecific Engager

Daniele Caracciolo, Carlo Gentile, Sara Squillacioti, Stefania Signorelli, Caterina Riillo, Pinuccia Faviana, Francesco Conforti, Katia De Ieso, Elisabetta Procopio, Emanuela Altomare, Nicoletta Polerà, Maria Gaetano und 8 weitere

Hematological Oncology · 2026

DOI: 10.1002/hon.70187 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hematological Oncology, 2026. Verfasst von Daniele Caracciolo und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental and Clinical Medicine (DMSC), Magna Graecia University, Catanzaro, Italy. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Immunotherapy, CD3 Complex, Lymphoma, T-Cell. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of Health PSC Salute 2014-2020-POS4 "Cal-Hub-Ria", BiovelocITA, Fondazione Roche per la Ricerca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

T‐cell lymphomas (TCLs) account for a relatively small fraction of lymphoid malignancies and are characterized by highly aggressive course often refractory to current available therapies. We previously reported potent in vitro and in vivo antitumor activity of a Bispecific T‐Cell Engager (UMG1/CD3ε‐BTCE) directed against UMG1, a unique CD43 epitope that is abundantly expressed on T‐cell acute lymphoblastic leukemia (T‐ALL) and diffuse large B‐cell lymphoma (DLBCL) cells, while absent in most normal tissues, except thymocytes and a small fraction of peripheral blood T lymphocytes (< 5%). Here, we investigated the in vitro efficacy of UMG1/CD3ε‐BTCE against TCLs. IHC analysis of Tissue Micro Arrays (TMAs) revealed high UMG1 expression in 62.3% of TCL samples, including peripheral T‐cell lymphoma‐not otherwise specified (PTCL‐NOS) and ALK‐negative anaplastic large cell lymphoma (ALCL). Notably, all T‐PLL primary specimens (27/27) were positive, and 3 of 4 TCL cell lines also expressed UMG1 by flow cytometry. The asymmetric UMG1/CD3ε‐BTCE induced robust redirected cytotoxicity against UMG1‐expressing TCL cells. Moreover, this activity was strengthened by cell exposure to the HDAC inhibitor SAHA. We observed a dose‐dependent engaged T‐cell‐mediated cytotoxicity and inflammatory cytokine release, resulting in lysis of UMG1‐expressing cells, with no significant effect on UMG1‐not expressing cells. Our findings suggest that the UMG1/CD3ε‐BTCE selectively exerts potent anti‐tumor activity against a relevant subset of TCLs. These findings support the development of a precision immunotherapy approach for patients with UMG1‐expressing aggressive hematologic malignancies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificImmunotherapyCD3 ComplexLymphoma, T-CellHumansCell Line, Tumor

Stichwörter der Autor:innen

T‐PLLT‐cell lymphomasUMG1bispecific T‐cell engagerscancerimmunotherapylymphoma

Substanzen

Antibodies, BispecificCD3 Complex

Autor:innen und Institutionen

  • Department of Experimental and Clinical Medicine (DMSC), Magna Graecia University, Catanzaro, Italy.
  • Department of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, Pisa, Italy.
  • Pathology Unit, Annunziata Hospital, Cosenza, Italy.
  • Pathology Unit, A.O.U Dulbecco, Catanzaro, Italy.
  • IRIB-CNR, Catanzaro, Italy.
  • Laboratory of Onco-Hematology, Assistance Publique-Hôpitaux de Paris, Hôpital Necker Enfants-Malades, Paris, France.

Förderung

  • Italian Ministry of Health PSC Salute 2014-2020-POS4 "Cal-Hub-Ria"
  • BiovelocITA
  • Fondazione Roche per la Ricerca
  • Italian Ministry of Health, Ricerca Corrente 2024

Zitieren

APA

Caracciolo, D., Gentile, C., Squillacioti, S., Signorelli, S., Riillo, C., Faviana, P., Conforti, F., De Ieso, K., Procopio, E., Altomare, E., Polerà, N., Gaetano, M., Balducci, E., Beganovic, O., Tuccillo, F. M., Bonelli, P., Grillone, K., Lhermitte, L., Tagliaferri, P., & Tassone, P. (2026). UMG1 Defines a Targetable Subset of T‐Cell Lymphomas and Enables Precision Immunotherapy With a First‐in‐Class CD3ε Bispecific Engager. Hematological Oncology. https://doi.org/10.1002/hon.70187

Vancouver

Caracciolo D, Gentile C, Squillacioti S, Signorelli S, Riillo C, Faviana P, et al. UMG1 Defines a Targetable Subset of T‐Cell Lymphomas and Enables Precision Immunotherapy With a First‐in‐Class CD3ε Bispecific Engager. Hematological Oncology. 2026. doi:10.1002/hon.70187

BibTeX
@article{Caracciolo2026,
  author = {Caracciolo, Daniele and Gentile, Carlo and Squillacioti, Sara and Signorelli, Stefania and Riillo, Caterina and Faviana, Pinuccia and Conforti, Francesco and De Ieso, Katia and Procopio, Elisabetta and Altomare, Emanuela and Polerà, Nicoletta and Gaetano, Maria and Balducci, Estelle and Beganovic, Omer and Tuccillo, Franca Maria and Bonelli, Patrizia and Grillone, Katia and Lhermitte, Ludovic and Tagliaferri, Pierosandro and Tassone, Pierfrancesco},
  title = {UMG1 Defines a Targetable Subset of T‐Cell Lymphomas and Enables Precision Immunotherapy With a First‐in‐Class CD3ε Bispecific Engager},
  journal = {Hematological Oncology},
  year = {2026},
  doi = {10.1002/hon.70187}
}
Kostenlos starten →